Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests pharmacist coaching to boost RA drug adherence

NCT ID NCT05413759

Disease control Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether extra support from a pharmacist—starting in the hospital and continuing after discharge—can help people with rheumatoid arthritis take their disease-modifying medications more consistently. Two hundred participants will either receive this pharmaceutical care or usual follow-up. The main goal is to see if the intervention improves medication adherence after 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pharmaceutical care (medication reconciliation and motivational interviews)
What this could lead to
If successful, this approach could help more rheumatoid arthritis patients take their medications as prescribed, potentially improving disease control and quality of life.
What could go wrong
This is a relatively small, early-stage study focused on adherence, not a new treatment. The intervention may not significantly change behavior or health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with diagnosed rheumatoid arthritis (RA), * Patient, male or female, aged 18 or over, * Patient hospitalized or coming for a consultation in a rheumatology department, and returned home at hospital discharge * Patient having DMARDs for RA (continuation or initiation) comprising at least methotrexate and/or a tsDMARD (targeted synthetic DMARD, JAK inhibitor) and/or subcutaneous bDMARD (biologic DMARD), * Autonomous patient in the management of his drug treatment, * Patient understanding and speaking French, * Patient affiliated to the French general national health insurance or similar, * Patient having given his free, informed and signed consent. Exclusion Criteria: * Patient whose usual pharmacy already has or has had a patient included in the INTERVENTION group in the study, * Patient whose regular pharmacy is currently treating another patient. * Patient with obvious significant cognitive or psychiatric disorders incompatible with the study (according to the judgment of the investigator), * Patient whose management of his drug treatment at home is carried out exclusively by a carer, * Patient participating in another research that may interfere (investigator's judgement) with the results of the present study, * Adult patient protected under the terms of the law (Public Health Code), * Patient not fit to carry out the follow-up, according to the judgment of the investigator, * Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Medication Adherence rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Service de rhumatologie et pathologie osseuse - Hôpital Edouard Herriot

    RECRUITING

    Lyon, 69003, France

  • Service de rhumatologie, Centre Hospitalier Lyon Sud, Groupement Hospitalier Sud, Hospices Civils de Lyon

    NOT_YET_RECRUITING

    Pierre-Bénite, Lyon, 69495, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.